KRAS and non-small cell lung carcinoma: Although this outcome clearly differs from the 2.41 years previously reported in the LCMC cohort [4], it resembles the OS recently reported in a retrospective analysis of chemotherapy-treated patients with advanced NSCLC and KRAS activating mutations (8.8 months vs. 13.5 months, p = 0.038, in KRAS-mutated and –WT, respectively) [32].